Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
about
Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco mouse.The New Biology and Pharmacology of Glucagon.GLP-1/glucagon receptor co-agonism for treatment of obesity.Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly.Development and characterisation of a novel glucagon like peptide-1 receptor antibody.Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.Gut hormone polyagonists for the treatment of type 2 diabetes.Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.ZP2495 Protects against Myocardial Ischemia/Reperfusion Injury in Diabetic Mice through Improvement of Cardiac Metabolism and Mitochondrial Function: The Possible Involvement of AMPK-FoxO3a Signal Pathway.Oxyntomodulin analogue increases energy expenditure via the glucagon receptor.Are peptide conjugates the golden therapy against obesity?MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 studyFuture Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
P2860
Q33825537-DBE42E08-42B5-4239-B8FA-CD8760B909F1Q38919742-E6100A75-B5C1-4AA8-9288-066FB2EB5DB8Q39451553-86C3CF12-648C-4F20-BBF9-A2FC00B720C0Q42380173-A2B880CC-E8D4-43B6-8545-79E97F05D65FQ47366967-887C8BF2-73CB-4654-8E11-52733FF6F552Q47625288-7D1B543E-694C-4C09-9562-DA384FF22CF0Q47779219-F5D7D857-6C71-4731-83BA-D348A988CC07Q49218095-C14C8149-C851-41B3-8AAC-D8FC422E5D35Q49394966-D6DFBE17-6410-468F-8599-0389098C0597Q51731634-C3B2156C-5F1A-459F-82C3-E88DCC6C131BQ54981530-5E3F4F3E-9171-4F80-AD0A-590B7FF74704Q55427238-70574AF7-6D15-4CB0-BE29-730B83CED282Q56967870-4C150822-1205-45DD-998B-425762C2320BQ59136513-67A5E2C5-F2B0-48F1-AC1B-8D4FFFAB8D8A
P2860
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Robust anti-obesity and metabo ...... rodents and non-human primates
@ast
Robust anti-obesity and metabo ...... rodents and non-human primates
@en
type
label
Robust anti-obesity and metabo ...... rodents and non-human primates
@ast
Robust anti-obesity and metabo ...... rodents and non-human primates
@en
prefLabel
Robust anti-obesity and metabo ...... rodents and non-human primates
@ast
Robust anti-obesity and metabo ...... rodents and non-human primates
@en
P2093
P2860
P356
P1476
Robust anti-obesity and metabo ...... rodents and non-human primates
@en
P2093
C M Rondinone
D C Hornigold
L Jermutus
M A Bednarek
P2860
P304
P356
10.1111/DOM.12735
P577
2016-08-15T00:00:00Z